In the second trial , we determined and compared the efficacy of a series of CP doses ( @ -LSB- CP@ -RSB- , @ -LSB- CP@ -RSB- , @ -LSB- CP@ -RSB- , and @ -LSB- CP@ -RSB- mol ) against high intensity infections .